MXCT Stock Overview
A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MaxCyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.98 |
| 52 Week High | UK£4.30 |
| 52 Week Low | UK£1.70 |
| Beta | 1.13 |
| 11 Month Change | -9.70% |
| 3 Month Change | -20.53% |
| 1 Year Change | 2.76% |
| 33 Year Change | -74.53% |
| 5 Year Change | 144.26% |
| Change since IPO | 289.54% |
Recent News & Updates
Recent updates
MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 09
Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%
May 30Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results
May 10Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
Mar 14Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Mar 07Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%
Oct 07Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Aug 12MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 15Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%
May 14We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Apr 27Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth
Nov 20Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Mar 02We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Nov 17We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn
Jul 25MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain
Feb 22Shareholder Returns
| MXCT | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -8.3% | 10.9% | -2.4% |
| 1Y | 2.8% | -25.7% | 7.6% |
Return vs Industry: MXCT exceeded the UK Life Sciences industry which returned -25.7% over the past year.
Return vs Market: MXCT underperformed the UK Market which returned 7.6% over the past year.
Price Volatility
| MXCT volatility | |
|---|---|
| MXCT Average Weekly Movement | 6.5% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: MXCT's share price has been volatile over the past 3 months.
Volatility Over Time: MXCT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 143 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
| MXCT fundamental statistics | |
|---|---|
| Market cap | UK£313.17m |
| Earnings (TTM) | -UK£26.98m |
| Revenue (TTM) | UK£34.60m |
9.1x
P/S Ratio-11.6x
P/E RatioIs MXCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MXCT income statement (TTM) | |
|---|---|
| Revenue | US$45.44m |
| Cost of Revenue | US$5.26m |
| Gross Profit | US$40.18m |
| Other Expenses | US$75.61m |
| Earnings | -US$35.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 88.43% |
| Net Profit Margin | -77.97% |
| Debt/Equity Ratio | 0% |
How did MXCT perform over the long term?
See historical performance and comparison